Effects of Wheat Bran Extract on Cognitive and Memory Function

March 13, 2016 updated by: Soo-Wan Chae, Chonbuk National University Hospital

Efficacy and Safety of Wheat Bran Extract on Improvement of Cognitive and Memory Function

The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of water extract from wheat Triticum aestivum L on cognitive and memory function. The investigators measured changes in cognitive function parameters, including CNT, WMT, K-MMSE, BCRS, PRMQ, PSS, SF-36 and BDNF

Study Overview

Detailed Description

Based on reports about the neuroprotective effects of water extract from wheat Triticum aestivum L. or its bran, the investigators hypothesize that extract of wheat bran (WBE) is beneficial to elderly people with age-associated cognitive impairment. The investigators investigated the efficacy and safety of WBE on improvement of cognitive function through measuring the neuropsychometric assessments in adult with subjective cognitive impairment by a randomized clinical trial.

Seventy participants aged from 50 to 80 years old with subjective cognitive impairment were randomly assigned to receive either WBE (3,000 mg/day) in this 12-week, double-blind placebo-controlled and parallel trial. Neuropsychological assessments including Computerized Neurocognitive function test (CNT), Working Memory Test (WMT), Korean Mini-Mental State Examination (K-MMSE), Brief Cognitive Rating Scale (BCRS), Prospective and Retrospective Memory Questionnaire (PRMQ), Perceived Stress Scale (PSS), 36-Item of Short-Form Health Survey (SF-36) and blood Brain-derived neurotrophic factor (BDNF) were used to assess the cognitive function before and after the intervention.

Study Type

Interventional

Enrollment (Actual)

70

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

48 years to 78 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • subjects with subjective cognitive impairment
  • able to give informed consent

Exclusion Criteria:

  • history of underlying neurodegenerative disease
  • allergic or hypersensitive to any of the ingredients in the test products
  • history of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery
  • history of alcohol or substance abuse
  • participation in any other clinical trials within past 2 months
  • laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study etc.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo group
placebo
Placebo
Experimental: WBE group
wheat bran extract
wheat bran extract (3 g/day)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Cognitive function as assessed by the visual learning test score of CNT (computerized neurocognitive test)
Time Frame: baseline and 12 weeks
baseline and 12 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Visual subset of WMT (working memory test)
Time Frame: baseline and 12 weeks
baseline and 12 weeks
Cognitive function as assessed by the CNT (Computerized Neurocognitive Test) score
Time Frame: baseline and 12 weeks
baseline and 12 weeks
Cognitive function as assessed by the Verbal subtest of WMT (Working Memory Test)
Time Frame: baseline and 12 weeks
baseline and 12 weeks
Cognitive function as assessed by the BCRS (Brief Cognitive Rating Sclae)
Time Frame: baseline and 12 weeks
baseline and 12 weeks
Memory function as assessed by the PRMQ (Prospective and Retrospective Memory Questionnaire)
Time Frame: baseline and 12 weeks
baseline and 12 weeks
Stress level evaluation as assessed by the Perceived stress scale (PSS)
Time Frame: baseline and 12 weeks
baseline and 12 weeks
Quality of life as assessed by the 36-item short-form healthy survey (SF-36) score
Time Frame: baseline and 12 weeks
baseline and 12 weeks
Cognitive function as assessed by the Brain-Derived Neurotrophic Factor (BDNF)
Time Frame: baseline and 12 weeks
baseline and 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2013

Primary Completion (Actual)

September 1, 2014

Study Completion (Actual)

February 1, 2015

Study Registration Dates

First Submitted

June 30, 2015

First Submitted That Met QC Criteria

July 1, 2015

First Posted (Estimate)

July 3, 2015

Study Record Updates

Last Update Posted (Estimate)

March 15, 2016

Last Update Submitted That Met QC Criteria

March 13, 2016

Last Verified

March 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • CTCF2_2013_WBE

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognitive Function 1, Social

Clinical Trials on Placebo

3
Subscribe